{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:12:03Z","timestamp":1789179123551,"version":"build-2803163510"},"reference-count":99,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2022,1,2]]},"DOI":"10.1080\/13543784.2022.2022120","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T23:01:35Z","timestamp":1640127695000},"page":"31-40","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Plexiform neurofibroma: shedding light on the investigational agents in clinical trials"],"prefix":"10.1080","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9757-5059","authenticated-orcid":false,"given":"Simge","family":"Acar","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA"},{"name":"School of Medicine, Ko\u00e7 University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7784-0476","authenticated-orcid":false,"given":"Amy E.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, Mo, USA"},{"name":"Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1719-0771","authenticated-orcid":false,"given":"Angela C.","family":"Hirbe","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA"},{"name":"Division of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, Mo, USA"},{"name":"Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,12,28]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-64076-5.00051-X"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70063-8"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.5-6-477"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03443-6"},{"issue":"4","key":"cit0005","first-page":"1819","volume":"27","author":"Mautner VF","year":"2007","journal-title":"Anticancer Res"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2008-011"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-3204"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy013"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(97)70092-1"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3911"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.03.073"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.05.018"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ne.16.030193.001151"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.772979"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1038\/189766a0"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1038\/335088a0"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1038\/nri2327"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.195"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy067"},{"issue":"1","key":"cit0020","first-page":"i134","volume":"2","author":"Gross AM","year":"2020","journal-title":"Neurooncol Adv"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-020-04731-2"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1172\/JCI60578"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-5032"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa222.619"},{"key":"cit0025","unstructured":"Study to investigate safety, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of trametinib in subjects with cancer or plexiform neurofibromas and trametinib in combination with dabrafenib in subjects with cancers harboring V600 mutations. https:\/\/ClinicalTrials.gov\/show\/NCT02124772."},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02220"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-27"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1798930"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2483"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605943"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912735"},{"key":"cit0032","unstructured":"Intermittent dosing of selumetinib in childhood NF1 associated tumours. https:\/\/ClinicalTrials.gov\/show\/NCT03326388."},{"key":"cit0033","unstructured":"MEK 1\/2 inhibitor selumetinib (AZD6244 hydrogen sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas. https:\/\/ClinicalTrials.gov\/show\/NCT02407405."},{"key":"cit0034","unstructured":"Efficacy and safety of selumetinib in adults with NF1 who have symptomatic, inoperable plexiform neurofibromas. https:\/\/ClinicalTrials.gov\/show\/NCT04924608."},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001819"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-2993-y"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.152"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6442-2"},{"key":"cit0039","unstructured":"Treatment of NF1-related plexiform neurofibroma with trametinib. https:\/\/ClinicalTrials.gov\/show\/NCT03741101."},{"key":"cit0040","unstructured":"Study to evaluate the safety, tolerability, PK characteristics and anti-tumor activity of FCN-159 in adult and pediatric participants with neurofibromatosis type 1. https:\/\/ClinicalTrials.gov\/show\/NCT04954001."},{"issue":"16","key":"cit0041","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1158\/1538-7445.AM2020-1951","volume":"80","author":"Lin S","year":"2020","journal-title":"Cancer Res"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1883"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25546"},{"key":"cit0044","unstructured":"MEK inhibitor mirdametinib (PD-0325901) in patients with neurofibromatosis type 1 associated plexiform neurofibromas. https:\/\/ClinicalTrials.gov\/show\/NCT03962543."},{"key":"cit0045","unstructured":"Individual patient compassionate use of mirdametinib. https:\/\/ClinicalTrials.gov\/show\/NCT05028166."},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30142-6"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0503224102"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.4161\/cc.11.2.19022"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24783"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.00460.x"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou235"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24873"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.09.016"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1111\/ped.14183"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1038\/35036374"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.19-14-05731.1999"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.08.041"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-009-0049-4"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70414-X"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.134"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107760"},{"key":"cit0063","unstructured":"Study of tasigna\u00ae\/nilotinib (AMN107) in neurofibromatosis (NF1) patients with plexiform neurofibromas. https:\/\/ClinicalTrials.gov\/show\/NCT01275586."},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0264"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-91442-8_5"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01193-6"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1443"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23015"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24281"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-88703-9"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2019.12.017"},{"key":"cit0072","unstructured":"AZD2171 in treating patients with neurofibromatosis type 1 and plexiform neurofibroma and\/or neurofibroma near the spine. https:\/\/ClinicalTrials.gov\/show\/NCT00326872."},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14332"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-011811-132441"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.2.5.446"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25763"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0237"},{"key":"cit0078","unstructured":"Study of sutent\u00ae\/sunitinib (SU11248) in subjects with NF-1 plexiform neurofibromas. https:\/\/ClinicalTrials.gov\/show\/NCT01402817."},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov245"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0204"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02589-6"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-838946"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1696"},{"key":"cit0084","unstructured":"PLX3397 in children and young adults with refractory leukemias and refractory solid tumors including neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN). https:\/\/ClinicalTrials.gov\/show\/NCT02390752."},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.1999.276.2.L311"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1992.tb03736.x"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1155\/S1110724304308107"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2007.01.009"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25041"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000243231.12248.67"},{"issue":"16","key":"cit0091","first-page":"3569","volume":"55","author":"Yan N","year":"1995","journal-title":"Cancer Res"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.8638"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou004"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3214"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1080\/08977190400000833"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2004.00204.x"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.10.1461"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318207b031"},{"issue":"2","key":"cit0099","first-page":"289","volume":"19","author":"Jakacki RI","year":"2017","journal-title":"Neuro Oncol"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2022.2022120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T21:18:33Z","timestamp":1674163113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2022.2022120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,28]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,2]]}},"alternative-id":["10.1080\/13543784.2022.2022120"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2022.2022120","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-10-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}